Patents by Inventor William A. Kinney

William A. Kinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF RADIATION DERMATITIS AND OTHER SKIN DISORDERS
    Publication number: 20220409578
    Abstract: Methods, compounds and compositions for treating and preventing dermatological disorders and ocular irritancy are disclosed. The compounds and compositions comprise a functionalized 1,3-benzene diol, such as 5-(2-(1H-1,2,3-triazol-1-yl)ethyl)-2-((1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-enyl)benzene-1,3-diol and ethyl 3-(3,5-dihydroxy-4-((1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-enyl)benzyl)azetidine-1-carboxylate.
    Type: Application
    Filed: November 13, 2020
    Publication date: December 29, 2022
    Inventors: Douglas BRENNEMAN, William A. KINNEY, Mark E. MCDONNELL, Dean PETKANAS
  • ALDEHYDE CONJUGATES AND USES THEREOF
    Publication number: 20220354857
    Abstract: The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: April 13, 2021
    Publication date: November 10, 2022
    Inventors: Todd Brady, Scott Young, William A. Kinney
  • Deuterated compounds and uses thereof
    Patent number: 11459300
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: October 4, 2022
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS
    Publication number: 20220257620
    Abstract: The invention relates to compositions containing certain phosphatidylcholines containing long chain polyunsaturated fatty acids in the sn-1 position or both the sn-1 and sn-2 positions as a neuroprotective agent, and further to treating or preventing oxidative stress in a neuronal tissue with such compositions.
    Type: Application
    Filed: June 26, 2020
    Publication date: August 18, 2022
    Inventors: Douglas E. BRENNEMAN, William A. KINNEY, Jason CLEMENT, Dean PETKANAS
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20220202745
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: March 7, 2022
    Publication date: June 30, 2022
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20210347735
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: May 19, 2021
    Publication date: November 11, 2021
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • DRUG DELIVERY AND IMAGING CHEMICAL CONJUGATE, FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20210277016
    Abstract: The present invention relates to compounds, and methods of use thereof, capable of entering macrophages. The invention further relates to compounds capable of modulating (for example inhibiting) the activity of the mammalian target of rapamycin (mTor), treating mTor-associated diseases, in particular, but not limited to, related to mTor in macrophages. The invention also relates to compounds capable of imaging mTor in a subject, in particular, but not limited to, mTor in macrophages.
    Type: Application
    Filed: May 26, 2021
    Publication date: September 9, 2021
    Inventors: Steven Jay Adelman, H. Donlon Skerrett, William A. Kinney
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20210275469
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: April 12, 2021
    Publication date: September 9, 2021
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Deuterated compounds and uses thereof
    Patent number: 11046650
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: June 29, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
    Patent number: 11034701
    Abstract: The present invention relates to compounds of Formula 1, and methods of use thereof, capable of entering macrophages. The invention further relates to compounds capable of modulating (for example inhibiting) the activity of the mammalian target of rapamycin (mTor), treating mTor-associated diseases, in particular, but not limited to, related to mTor in macrophages. The invention also relates to compounds capable of imaging mTor in a subject, in particular, but not limited to, mTor in macrophages.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: June 15, 2021
    Assignee: NANOPHAGIX LLC
    Inventors: Steven Jay Adelman, H. Donlon Skerrett, William A. Kinney
  • Toxic aldehyde related diseases and treatment
    Patent number: 11007157
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: May 18, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Substituted aminothiazoles
    Patent number: 10913734
    Abstract: Described herein are substituted aminothiazoles, compositions comprising same; and methods of making and using same.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: February 9, 2021
    Inventors: Yanming Du, Huagang Lu, John Rogowsky, William A. Kinney, Andrea Cuconati
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20200368182
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: January 27, 2020
    Publication date: November 26, 2020
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • DEUTERATED FORMS OF AMINOSTEROLS AND METHODS OF USING THE SAME
    Publication number: 20200262864
    Abstract: Described are deuterated forms of aminosterols, or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms at one or more positions selected from C1, C2, C3, C4, C5, C6, C7, C8, C9, C11, C12, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, and C27, are replaced with deuterium.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 20, 2020
    Applicant: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff, William A. Kinney, Stephen Jones, Scott Ashford, Anton Bieliauskas, Edward Hessler, Tom Fevig, Harold Karnes
  • ALDEHYDE CONJUGATES AND USES THEREOF
    Publication number: 20200246345
    Abstract: The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: October 3, 2019
    Publication date: August 6, 2020
    Inventors: Todd Brady, Scott Young, William A. Kinney
  • DEUTERATED COMPOUNDS AND USES THEREOF
    Publication number: 20200199075
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Toxic aldehyde related diseases and treatment
    Patent number: 10588874
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 17, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Deuterated compounds and uses thereof
    Patent number: 10550085
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: February 4, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Susan Macdonald
  • Toxic aldehyde related diseases and treatment
    Patent number: 10543181
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 28, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20190247334
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 15, 2019
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell